An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of FTY720 and Metabolites in Subjects With Severe Renal Impairment With That in Matched Healthy Control Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Novartis
- 04 Sep 2008 New trial record.